Table 2.
Exploratory analysis of characteristics associated with mortality or loss to follow-up at 12 months for patients with documented T1a HIV-associated Kaposi sarcoma (N=103) treated in the Neno Kaposi Sarcoma Clinic (March 2008 to February 2012)
| Unadjusted | Adjustedb | ||||
|---|---|---|---|---|---|
|
|
|
||||
| Characteristic | HR | 95% CI | HR | 95% CI | |
| Age at enrolment | ≥50 years | 1.05 | (0.31, 3.55) | 1.68 | (0.32, 8.76) |
| <50 years | 1.00 | ||||
| Sex | Female | 0.44 | (0.13, 1.48) | 0.30 | (0.06, 1.52) |
| Male | 1.00 | ||||
| ART duration at time of first chemotherapy | 1 week increase in ART duration | 0.97 | (0.93, 1.01) | 0.98 | (0.93, 1.03) |
| Baseline body mass index (BMI) | <19 kg/m2 | 3.91c | (1.51, 10.11) | 4.10c | (1.06, 15.89) |
| ≥19 kg/m2 | 1.00 | ||||
| Baseline haemoglobin (g/dL) | 1 g/dL decrease | 1.27c | (1.01, 1.61) | 1.52c | (1.03, 2.25) |
| Chemotherapy regimen | Second-line paclitaxel | 0.44 | (0.13, 1.51) | 0.49 | (0.10, 2.44) |
| First-line paclitaxel | 0.94 | (0.31, 2.82) | 0.71 | (0.08, 6.41) | |
| Bleomycin plus vincristine | 1.00 | ||||
| Grade 3/4 adverse event on treatment | Yes | 1.63 | (0.66, 4.05) | 1.05 | (0.31, 3.54) |
| No | 1.00 | ||||
a
T1: patients presenting with Kaposi sarcoma-associated oedema or ulceration, extensive oral mucosa KS, or visceral involvement
b
HR estimated by Cox-proportional hazard modelling, adjusting for remaining variables presented in the table
c
statistically significant association with death or loss to follow-up at 12 months (p≤0.05).
HR: hazard ratio; ART: antiretroviral therapy.